Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 24 December 2004:
Vol. 306. no. 5705, p. 2170
DOI: 10.1126/science.306.5705.2170a
Prev | Table of Contents | Next

News of the Week

CLINICAL TRIALS:
Halt of Celebrex Study Threatens Drug's Future, Other Trials

Jennifer Couzin

New research indicates Pfizer's COX-2 inhibitor Celebrex may cause increased risk of heart attacks and strokes, leading to the halting of some clinical trials involving the drug. Dozens of other COX-2 inhibitor trials are undergoing careful review. The scenario is strikingly similar to what happened this fall to Merck's COX-2 inhibitor Vioxx, which the Food and Drug Administration subsequently removed from the market.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)